STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Active, not recruiting
- Carcinoma, Small Cell Lung
- Atezolizumab
- +4 more
- Beijing City, China
- +7 more
2022-04-06
Apr 6, 2022M
E
Recruiting
- Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Everolimus
- +3 more
- Atlanta, Georgia
- +3 more
2021-07-15
Jul 15, 2021S
Recruiting
- Acute Lymphoblastic Leukemia
- Seoul, Daehangno, Jongno-gu, Korea, Republic ofSeoul National University Hospital
2021-06-15
Jun 15, 2021N
Completed
- Peripheral T-cell Lymphoma
- Selinexor
- ICE Chemotherapy
- Singapore, SingaporeNational Cancer Centre Singapore
2021-04-27
Apr 27, 2021S
Recruiting
- Hodgkin Lymphoma
- Nivolumab
- +3 more
- Saint Petersburg, Pesochny, Russian Federation
- +2 more
2021-07-19
Jul 19, 2021C
Not yet recruiting
- Small-cell Lung Cancer
- camrelizumab
- +3 more
- (no location specified)
2020-12-23
Dec 23, 2020S
Unknown status
- SCLC
- Anlotinib
- Anlotinib hydrochloride
- +2 more
- Shanghai, Shanghai, ChinaShanghai Chest hospital
2020-12-22
Dec 22, 2020C
Completed
- Breast Cancer
- apatinib+oral etoposide
- Beijing, Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
2020-12-01
Dec 1, 2020H
U
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Brentuximab Vedotin
- +4 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2021-12-29
Dec 29, 2021V
Terminated
- Small Cell Lung Carcinoma
- Durvalumab + Tremelimumab in combination with carboplatin and etoposide
- Durvalumab in combination with carboplatin and etoposide
- Omaha, NebraskaUniversity of Nebraska Medical Center
2022-02-24
Feb 24, 2022S
Completed
- Ovarian Cancer
- Apatinib
- Etoposide
- Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
2020-12-03
Dec 3, 2020C
Completed
- Lymphoma
- filgrastim
- +4 more
- (no location specified)
2021-06-16
Jun 16, 2021F
Recruiting
- Lung Neoplasm
- +2 more
- Camrelizumab combined with Apatinib, Etoposide and Cisplatin
- Fuzhou, Fujian, ChinaThe 900th Hospital of Joint Logistic Support Force
2021-02-03
Feb 3, 2021B
Recruiting
- Ovarian Sex Cord Stromal Tumor
- +2 more
- Paclitaxel
- +4 more
- Jinan, Shandong, ChinaQilu Hospital of Shandong University
2021-10-07
Oct 7, 2021Z
Recruiting
- Hemophagocytic Syndrome
- T/NK-Cell Lymphoma
- Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum
- Zhengzhou, Henan, ChinaOncology Department of The First Affiliated Hospital of Zhengzho
2021-08-03
Aug 3, 2021P
Recruiting
- Relapsed Solid Tumors
- +3 more
- Carfilzomib
- +2 more
- Phoenix, Arizona
- +7 more
2021-07-06
Jul 6, 2021B
Recruiting
- Ovarian Germ Cell Cancer
- +2 more
- Paclitaxel
- +4 more
- Jinan, Shandong, ChinaQilu Hospital of Shandong University
2021-10-07
Oct 7, 2021C
Recruiting
- Small Cell Lung Carcinoma
- CC-90011
- +4 more
- Marseille Cedex 5, France
- +12 more
2022-01-21
Jan 21, 2022T
Recruiting
- Ependymoma
- +3 more
- Ibrutinib
- +3 more
- Augusta, GeorgiaAugusta University, Georgia Cancer Center
2022-03-20
Mar 20, 2022M
Terminated
- HER-2 Positive Metastatic Breast Cancer
- Etoposide
- Trastuzumab
- Washington, District of ColumbiaWashington Cancer Institute
2020-11-10
Nov 10, 2020N
Active, not recruiting
- Breast Cancer
- Brain Metastases
- BEEP regimen
- Kaohsiung, Taiwan
- +7 more
2021-05-06
May 6, 2021C
Completed
- Hodgkin's Disease
- Non-Hodgkin's Lymphoma
- Vorinostat
- +2 more
- New York, New YorkCenter for Lymphoid Malignancies at CUMC
2020-11-05
Nov 5, 2020B
Not yet recruiting
- Small-cell Lung Cancer
- Carboplatin
- +3 more
- New York, New YorkColumbia University Irving Medical Center, Herbert Irving Compre
2021-08-02
Aug 2, 2021